Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.
Metrics to compare | AVCT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAVCTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.8x | −4.0x | −0.6x | |
PEG Ratio | 0.08 | −0.05 | 0.00 | |
Price/Book | 1,640.3x | 4.5x | 2.6x | |
Price / LTM Sales | 2,090.3x | 11.7x | 3.4x | |
Upside (Analyst Target) | 59.1% | 172.4% | 44.4% | |
Fair Value Upside | Unlock | −5.9% | 6.1% | Unlock |